Scynexis reports Q3 EPS (17c), consensus (20c)

Reports Q3 revenue $334,000, consensus $147,670. “Over the last several weeks, SCYNEXIS (SCYX) realized two significant achievements that we believe position our company for significant growth and success,” said David Angulo, M.D., President and Chief Executive Officer. “First, we announced the positive SAD/MAD data for our second-generation fungerp drug candidate, SCY-247, demonstrating that orally administered SCY-247 was well tolerated and achieved the estimated efficacy exposure at doses lower than the first generation fungerp (ibrexafungerp). We are excited about the favorable tolerability and pharmacokinetics of SCY-247 and look forward to commencing a Phase 2 study in invasive candidiasis, aiming to release proof of concept data in 2026. Secondly, we announced a successful resolution of our disagreement with GSK, which led to the one time payments of $24.8 million to SCYNEXIS which we will receive in Q4 of 2025. This influx of new capital coupled with our cash and investments on hand, results in a cash runway of more than two years, including the anticipated cost of SCY-247 development activities.”